Zoetis Faces Q3 Earnings Miss and Librela Sales Drop
Impax US Sustainable Economy Fund holds Zoetis for its strong governance and sustainability profile despite a Q3 earnings miss driven by a steeper-than-expected Librela sales decline. Zoetis’s animal-health pipeline won’t drive revenue until 2027, and shares traded between $115 and $177 over the past year.
1. Impax Fund’s Position
Impax US Sustainable Economy Fund holds Zoetis based on its attractive sustainability opportunity profile and strong governance credentials, viewing the animal-health business as structurally advantaged amid long-term demand trends.
2. Q3 Earnings and Librela Decline
In the third quarter, Zoetis reported results below expectations as Librela sales fell more than anticipated due to lingering side-effect perceptions, weighing on overall revenue performance.
3. Product Pipeline and Growth Timeline
Zoetis maintains a broad pipeline of new medicines and vaccines for livestock and companion animals, but significant revenue uplift from these products is not expected until 2027, with ongoing competition in established franchises.
4. Share Performance and Market Cap
Over the last 52 weeks, Zoetis shares fluctuated between $115 and $177, most recently closing near $126.56 and carrying a market capitalization above $55 billion.